Long‐term corticosteroid use, adrenal insufficiency and the need for steroid‐sparing treatment in adult severe asthma by Gurnell, Mark et al.
doi: 10.1111/joim.13273
Long-term corticosteroid use, adrenal insufficiency and the
need for steroid-sparing treatment in adult severe asthma
M. Gurnell1, L. G. Heaney2, D. Price3,4 & A. Menzies-Gow5
From the 1Metabolic Research Laboratories, Wellcome–MRC Institute of Metabolic Science, University of Cambridge, NIHR Cambridge
Biomedical Research Centre, Addenbrooke’s Hospital, Cambridge; 2Centre for Experimental Medicine, Queens University Belfast, Belfast,
UK; 3Observational and Pragmatic Research Institute Pte Ltd, Singapore, Singapore; 4Division of Applied Health Sciences, Centre of Academic
Primary Care, University of Aberdeen, Aberdeen; and 5Royal Brompton Hospital, London, UK
Abstract. Gurnell M, Heaney LG, Price D, Menzies-
Gow A (Addenbrooke’s Hospital, Cambridge;
Queens University Belfast, Belfast, UK;
Observational and Pragmatic Research Institute
Pte Ltd, Singapore, Singapore; University of
Aberdeen, Aberdeen; and Royal Brompton
Hospital, London, UK). Long-term corticosteroid
use, adrenal insufficiency and the need for steroid-
sparing treatment in adult severe asthma (Review).
J Intern Med 2021;https://doi.org/10.1111/joim.
13273
Secondary adrenal insufficiency (AI) occurs as the
result of any process that disrupts normal
hypothalamic and/or anterior pituitary function
and causes a decrease in the secretion of steroid
hormones from the adrenal cortex. The most com-
mon cause of secondary AI is exogenous corticos-
teroid therapy administered at supraphysiologic
dosages for ≥ 1 month. AI caused by oral corticos-
teroids (OCS) is not well-recognized or commonly
diagnosed but is often associated with reduced
well-being and can be life-threatening in the event
of an adrenal crisis. Corticosteroid use is common
in respiratory diseases, and asthma is a
representative condition that illustrates the poten-
tial challenges and opportunities related to corti-
costeroid-sparing therapies. For individuals with
severe asthma (approximately 5%–10% of all
cases), reduction or elimination of maintenance
OCS without loss of control can now be accom-
plished with biologic therapies targeting inflamma-
tory mediators. However, the optimal strategy to
ensure early identification and treatment of AI and
safe OCS withdrawal in routine clinical practice
remains to be defined. Many studies with biologics
have involved short evaluation periods and small
sample sizes; in addition, cautious approaches to
OCS tapering in studies with a placebo arm,
coupled with inconsistent monitoring for AI, have
contributed to the lack of clarity. If the goal is to
greatly reduce and, where possible, eliminate long-
term OCS use in severe asthma through the
increasing adoption of biologic treatments, there
is an urgent need for clinical trials that address
both the speed of OCS withdrawal and how to
monitor for AI.
Keywords: adrenal insufficiency, asthma, endocrinol-
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Introduction
The advent of modern disease-modifying biologic
therapies for the treatment of a diverse array of
medical conditions, including rheumatoid arthri-
tis, inflammatory bowel disease and asthma, offers
the prospect of significantly reducing the need for
long-term systemic corticosteroid therapy and its
attendant adverse effects (AEs). In the field of
asthma, treatments targeting inflammatory medi-
ators such as immunoglobulin E (IgE) (omal-
izumab), interleukin (IL)-4 and IL-13 (dupilumab),
and IL-5 (mepolizumab, reslizumab) or its receptor
(benralizumab) have proved particularly effective in
delivering disease control for severe asthma [1–3].
Thus, although corticosteroids retain an important
role in the management of acute exacerbations, the
long-held belief that a subgroup of patients with
the most severe disease will inevitably require
maintenance therapy with oral corticosteroids
(OCS) is being increasingly questioned.
Important challenges remain, however, since the
move away from long-term OCS therapy needs to
be delivered effectively and safely. For example,
many patients who might benefit from biologic
therapies remain unknown to specialist asthma
services and continue to receive treatment with
OCS at dosages that put them at significant risk of
adverse sequelae (e.g. hyperglycaemia/diabetes
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mellitus, hypertension, dyslipidaemia, premature
cardiovascular disease [CVD], osteopenia/osteo-
porosis and cataracts) [4, 5]. Equally important, for
those successfully treated with OCS-sparing bio-
logics, there remains the issue of how best to safely
wean off long-term corticosteroid therapy. Second-
ary adrenal insufficiency (AI) following exposure to
supraphysiologic exogenous corticosteroids is
common, yet under-recognized [6]. Too rapid wean-
ing and/or inappropriate cessation of physiologic
equivalent dosages in those with hypothalamic–
pituitary–adrenal (HPA) axis suppression is often
associated with impaired well-being and may be
life-threatening in the event of an adrenal crisis [7].
Here, we consider why AI should be an important
consideration for any asthma patient transitioning
from long-term OCS therapy in the era of biologics
and we examine the available evidence to guide
safe OCS withdrawal.
Normal HPA axis function
The adrenal cortex secretes mineralocorticoids (e.g.
aldosterone), glucocorticoids (e.g. cortisol) and sex
steroids (e.g. dehydroepiandrosterone) from 3 dis-
tinct layers: outer zona glomerulosa (ZG), middle
zona fasciculata (ZF) and inner zona reticularis
(ZR), respectively (Fig. 1a). Mineralocorticoid pro-
duction and release are governed by the renin–
angiotensin(–aldosterone) system (RAS/RAAS)
(Fig. 1b); in contrast, glucocorticoid and adrenal
sex steroid secretion are under the control of
hypothalamic corticotropin-releasing hormone
(CRH) and pituitary adrenocorticotropic hormone
(ACTH) (Fig. 1c). ACTH activation of the melano-
cortin 2 receptor (MC2R) – a G protein-coupled
receptor – on cells of the ZF, stimulates production
and release of several glucocorticoids including
cortisol, the primary ligand for the glucocorticoid
receptor (GR), which is a member of the steroid
nuclear receptor superfamily. ACTH is a key deter-
minant of adrenal gland growth and maturation,
and cortisol is required to maintain normal blood
pressure and blood glucose concentrations, along
with other aspects of homeostasis [8]. In addition
to mediating pleiotropic effects in multiple target
tissues, cortisol, operating through a classical
negative feedback loop, inhibits CRH and ACTH
release (Fig. 1c) [8–12]. Consistent with this, exoge-
nous corticosteroids can suppress HPA axis func-
tion and, if sustained, the resultant lack of
endogenous ACTH leads to adrenocortical hypo-
plasia or atrophy [8–10, 13–19].
Adrenal insufficiency
Epidemiology and aetiology
AI occurs when there is failure of normal adreno-
cortical function. Primary AI (often referred to by
the eponym Addison’s disease) is characterized by
glucocorticoid, mineralocorticoid and adrenal sex
steroid insufficiency and occurs relatively infre-
quently, with an estimated prevalence of 82 to 144
per million people [7, 20]. Autoimmune disease is
the most frequent cause of primary AI, but tuber-
culosis, fungal infections and human immunode-
ficiency virus can also lead to AI and are more
commonly seen in developing countries [21]. Other
causes are shown in Table 1. Secondary AI, in
which there is glucocorticoid insufficiency but the
preservation of mineralocorticoid production,
occurs more frequently than primary AI, with an
estimated prevalence of 150 to 280 per million
people [20]. Secondary AI may complicate any
process (i.e. disease, injury or drug) that disrupts
normal hypothalamic and/or anterior pituitary
function to cause a decrease in the secretion of
corticosteroid hormones from the adrenal cortex
(Table 1) [17].
The drug class most often associated with sec-
ondary AI is exogenous corticosteroids when used
at supraphysiologic dosages for 3 to 4 weeks or
longer [6, 9, 15, 17, 20, 22]. Surprisingly, however,
AI caused by OCS is still not well-recognized or
commonly diagnosed, despite being potentially one
of the most dangerous AEs of OCS therapy and
despite the evidence confirming that AI is common
[6, 15]. The risk of inducing AI with other routes of
administration (e.g. higher dosages of inhaled
corticosteroids) should also not be discounted
[23–25]; indeed, topical, inhaled, intranasal, oral
and injectable forms all pose a risk of AI [9, 17, 20,
22]. Moreover, many patients are taking exogenous
corticosteroids through more than one route (e.g.
intranasal and/or topical preparations for co-exis-
tent conditions such as nasal polyps or eczema,
respectively) and the effects may be additive in
terms of suppressing HPA axis function. Overall,
the potential to induce AI as a consequence of
exogenous corticosteroid use remains underappre-
ciated by many clinicians [10, 13, 14].
Risk of adrenal insufficiency with exogenous corticosteroid usage
Suppression of the HPA axis may occur even with
physiologic dose equivalents of exogenous
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corticosteroids, but is more commonly observed
following treatment with supraphysiologic dosages
[12, 13]. The higher the dosage and the longer the
duration of treatment, the greater the risk of
developing AI; however, systematic literature
reviews have not confirmed a clear relationship
between cumulative dosage or duration of corti-
costeroid therapy and AI [6, 15].
The risk of developing AI also has been linked with
specific aspects of the treatment regimen; for
example, an increased propensity to develop AI
was observed for patients receiving split daily
dosing, night-time dosing and total daily dosages
that exceed physiologic equivalents (e.g. ≥5 mg
prednisone/prednisolone) and with the use of
long-acting (e.g. dexamethasone) and/or systemic
corticosteroid preparations; in contrast, lower risk
was associated with the use of low maintenance
dosages (i.e. not exceeding physiologic equiva-
lents), single doses, morning only and/or alter-
nate-day dosing, short-acting corticosteroids (e.g.
hydrocortisone) and topical application [26].
The risk of AI is also related to the pharmacoki-
netics/pharmacodynamics of the OCS used (e.g.
bioavailability, protein-binding affinities, plasma
half-life and metabolic inactivation and clearance)
[13]. Repeat courses of OCS are also a risk factor
for AI [18], and patients with a predisposition to
HPA axis dysfunction as a consequence of other
underlying conditions or medications may be par-
ticularly susceptible to AI caused by OCS [27]. Still,
the risk of AI can be reduced, though not fully
negated, by using the lowest effective dosage of
OCS for the shortest amount of time [16].
Although the absolute risk of developing AI follow-
ing a short course of OCS is often assumed to be
low, clinically relevant HPA axis suppression may
be substantially under-recognized and under-re-
ported in clinical practice [9, 12, 19]. In a study by
Schuetz and colleagues, a 14-day course of sys-
temic corticosteroids (40 mg methylprednisolone
injection once followed by 13 days of 40 mg oral
prednisone) led to HPA axis suppression (as
gauged by response to the 1 µg corticotropin [syn-
thetic ACTH1-24] stimulation test) in 7 of 9 patients
on the first day following commencement of corti-
costeroid treatment; this increased to 8 of 9 by the
last day of therapy. Moreover, 21 days after dis-
continuation of treatment, 3 patients still had
evidence of adrenal dysfunction. Although all 9
patients had an underlying diagnosis of chronic
obstructive pulmonary disease and 5 were on




















Fig. 1 Schematic representation of the key pathways regulating secretion of cortisol and aldosterone. (a) Adrenal
structure/function correlations: the zona glomerulosa (ZG), zona fasciculata (ZF) and zona reticularis (ZF) secrete
aldosterone, cortisol and adrenal androgens respectively, whilst the innermost medulla is the source of catecholamines.
© Jolly E, Fry A, Chaudhry A, eds. Training in Medicine (Oxford Specialty Training: Training In). 1st ed. 2016. Oxford
University Press. Reproduced with permission of the Licensor through PLSclear. (b) Aldosterone synthesis and release are
governed principally by the renin–angiotensin system (RAS). From New England Journal of Medicine, Weber KT. N Engl J
Med. 2001;345:1689–1697. © 2020 Massachusetts Medical Society. Reprinted with permission from Massachusetts
Medical Society. (c) In contrast, cortisol and adrenal sex steroids are under the control of the hypothalamus and pituitary
gland, which together comprise the hypothalamic–pituitary–adrenal (HPA) axis. © CC BY NC ND. Hardy RS et al. Swiss Med
Wkly. 2012;142:w13650. https://smw.ch/about-us#c335.
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none had received systemic corticosteroid therapy
in the preceding 6 months [12].
Perhaps even more compelling are the findings of
Henzen and colleagues, who examined suppres-
sion and recovery of adrenal response (using 1 µg
corticotropin) in 75 hospitalized patients who were
receiving glucocorticoid treatment at an equivalent
of at least 25 mg prednisone daily for the first time
in their lives [28]. Overall, 41 (55%) patients were
classified as having a normal adrenal response; the
other 34 (45%) patients had stimulated plasma
cortisol levels below the predefined cut-off when
tested between 24 h and 72 h after stopping
glucocorticoid therapy. Those with a normal
response had similar durations of treatment (me-
dian 8 days [range: 5–30]) as those with sup-
pressed responses (median 10 days [range 5–30]),
as well as similar median daily and cumulative
dosages [28]. Although the majority of patients
showed a full recovery within 2 weeks, 2 patients
continued to demonstrate suboptimal responses
and required longer-term follow-up.
Individual variability in corticosteroid action and
metabolism (especially CYP3A4 activity) also influ-
ence the propensity to develop AI [9]. In a recent
systematic review examining systemic
Table 1 Causes of adrenal insufficiency (AI)
Primary AI
• Autoimmune adrenalitis (either in isolation or as part of autoimmune polyendocrine syndrome (APS) types 1 and 2)
• Infection (e.g. TB, HIV, CMV, histoplasmosis)
• Infiltration (e.g. amyloidosis, haemochromatosis, metastatic malignancya, lymphoma)
• Iatrogenic, for example, following:
a bilateral adrenalectomy;
b treatment with adrenal steroidogenesis inhibitors (e.g. metyrapone, ketoconazole, osilodrostat,
etomidate, mitotane);
c treatment with CYP3A4-inducing agents (e.g. rifampicin, phenytoin, mitotane)b
d treatment with CYP3A4 inhibitors (e.g. itraconazole, voriconazole)b
e treatment with immune checkpoint inhibitorsc (e.g. ipilimumab, nivolumab, pembrolizumab)
• Adrenal haemorrhage (e.g. Waterhouse-Friderichsen syndrome; antiphospholipid syndrome; anticoagulation)
• Congenital adrenal hyperplasia (CAH)
• Adrenoleukodystrophyd
• Resistance to ACTH (e.g. owing to loss-of-function mutations in MC2R gene)
Secondary AI
• Pituitary disorders (e.g. tumour, postsurgery or radiotherapy, pituitary apoplexy, trauma, infiltration, inflammation,
congenital)
• Hypothalamic disorders (sometimes denoted as tertiary AI; aetiologies overlap those of pituitary)
• Exogenous corticosteroid (glucocorticoid) therapye
AI, adrenal insufficiency; CMV, cytomegalovirus; HIV, human immunodeficiency virus; MC2R, melanocortin 2 receptor;
TB, tuberculosis.
aAdrenal metastases are relatively common with certain primary tumours (e.g. renal, bronchogenic, breast), but clinically
relevant AI is only rarely observed.
bDrugs that interfere with the activity of CYP3A4 can exert profound effects for those receiving exogenous glucocorticoid
therapy. For example, treatment with drugs that induce CYP3A4 leading to increased glucocorticoid metabolism can
predispose to hypoadrenalism for patients receiving fixed dosages of exogenous glucocorticoids (and in whom the HPA axis
is suppressed), whereas in those patients receiving treatment with CYP3A4 inhibitors, iatrogenic Cushing syndrome can
develop because of impaired metabolism of even lower dosages of exogenous glucocorticoids, which leads to
hypoadrenalism if the CYP3A4 inhibitor is discontinued and the remaining exogenous glucocorticoids are insufficient
to compensate for HPA axis suppression.
cSome cancer immunotherapy agents may predispose to the development of autoimmune adrenalitis.
dThe diagnosis of primary adrenal insufficiency in a young man mandates consideration of a rare but important cause –
adrenoleukodystrophy (ALD) – especially when there are features to suggest associated neurologic dysfunction. ALD is an
X-linked disorder caused by pathogenic variants in the ABCD1 gene (ATP-binding cassette subfamily D member 1), which
encodes an ABC transporter. This is critical for the uptake of very-long-chain fatty acids into the peroxisome, with
subsequent b-oxidation and breakdown. Accumulation of very-long-chain fatty acids in the central nervous system,
adrenal cortex and the Leydig cells of the testes leads to the well-recognized clinical features of ALD.
eExogenous corticosteroid therapy is a common, but poorly recognized, cause of adrenal insufficiency.
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glucocorticoid therapy and AI in adults, the median
percentage of patients with AI was 37.4% (in-
terquartile range: 13%–63%) [15], which could
translate to a substantial number of patients at
risk of AI since an estimated 2.5% of adults are
receiving prescribed corticosteroids for immune-
related or inflammatory conditions at any given
time [20, 21, 29]. In 1 year, 10 million new
prescriptions for systemic corticosteroids were
filled in the United States [20], whereas 8 million
were filled in the United Kingdom [15].
HPA axis recovery following exogenous corticosteroid exposure
Recovery of HPA axis function is unpredictable
[30], and there are little data that accurately
describe an expected time course for the recovery
of adrenal function [15, 31]. Following discontinu-
ation of exogenous corticosteroids, HPA axis sup-
pression may resolve quickly (within hours or days)
or persist, in some cases for up to 1 year or longer
[13]. Moreover, in some patients, endogenous cor-
tisol secretion remains permanently suppressed
[14]. Although even a single dose of corticosteroid
can cause HPA axis suppression (this is the basis
for the overnight dexamethasone suppression test
used to screen for Cushing syndrome), recovery is
usually rapid with no adverse clinical sequelae.
Longer courses (e.g. 4 weeks or more) have been
linked with longer recovery times, [10] and, as a
general rule, slow tapering after long-term OCS
usage is almost always necessary to support the
recovery of normal HPA axis function [30]. In this
context, complete HPA axis recovery is unlikely to
be observed until at least 4 weeks after cessation of
corticosteroids [10]. In a systematic review of
systemic glucocorticoid therapy and AI in adults,
75% of patients had persistent AI 10 weeks after
discontinuation of OCS (≥4 weeks of use), whereas
15% still had AI 3 years beyond discontinuation.
Glucocorticoid exposure varied significantly across
studies, but no obvious correlations were noted
when AI cases were stratified by dosage or duration
of corticosteroid use. Across all groups, 14% of
patients who received a medium cumulative
dosage (0.5–5.0 g) and 50% of those who received
a high cumulative dosage (>5.0 g) developed AI
[15].
Currently, there is little consensus as to the
optimum approach for safely tapering corticos-
teroids [13, 16, 21, 22, 32, 33]. The decision of
when and how to taper corticosteroids, and when
and how to monitor for AI, is usually at the
clinician’s discretion and based on signs and
symptoms of disease control [32]. The fear of
underlying AI may actually hinder a clinician’s
confidence in tapering OCS [30]. Ideally, tapering
should be individualized, with continuous moni-
toring of the disease and AEs [32].
Presentation of adrenal insufficiency
The clinical presentation of AI can vary widely, but
often includes several nonspecific features [12, 16,
17, 19, 22, 34]. Signs and symptoms of AI include
weakness, fatigue, malaise, gastrointestinal upset
(nausea, vomiting, diarrhoea, abdominal pain),
anorexia/weight loss, headache, fever, myalgia,
arthralgia, psychiatric symptoms and poor linear
growth and/or poor weight gain in children [16, 17,
21]. The mnemonic ‘HIGH STAKES’ can be used as
an aide-memoire for the signs, symptoms and
other important clinical features of AI (Fig. 2).
For patients with AI secondary to exogenous glu-
cocorticoid exposure, symptoms often develop after
complete (or near-complete) corticosteroid with-
drawal when the removal of exogenous glucocorti-
coid unmasks the lack of endogenous cortisol
production [11, 35]. Abrupt discontinuation of
OCS can cause AI to appear suddenly, especially
when HPA suppression is marked. However, in
those patients with partial suppression, clinical
features of AI may be mild or even absent, only
manifesting at times of acute stress [36]. If such an
event occurs weeks or months after OCS with-
drawal, the connection between HPA axis suppres-
sion and OCS use may not be made [12, 14, 17, 20,
37].
Importantly, therefore, even in patients with AI who
appear to be relatively asymptomatic (as observed
Hypotension with dizziness (especially postural)
Inability to mount acute stress response
Generalised aches and pains, back and leg cramps/spasms
Hypoglycaemia
Shock and fever in intercurrent illness/crisis
Tiredness/fague and weakness
Abdominal pain, anorexia, weight loss, nausea and voming, gastrointesnal upset
Skin hyperpigmentaon (in primary but not secondary adrenal insufficiency) 
Electrolyte disturbance [hyponatraemia (hyperkalaemia only if primary adrenal insufficiency)]
Somnolence, confusion, delirium or coma
Fig. 2 Clinical features of adrenal insufficiency.
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in some cases of secondary AI where there is preser-
vation of mineralocorticoid production), rapid
decompensation in response toanacute intercurrent
stress (e.g. infection, trauma, other acute critical
illness) can result in a life-threatening adrenal crisis
[8, 11, 12, 17, 19]. Even when this occurs, the
nonspecific nature of many of the clinical features
may mean that a diagnosis of hypoadrenalism is not
made in a timely manner [8, 12, 14, 16, 19, 22].
Laboratory clues to the underlying diagnosis include
hyponatraemia, hyperkalaemia (only in primary AI),
hypoglycaemia, hypercalcaemia, neutropenia,
eosinophilia, lymphocytosis andanaemia [38]. Vaso-
pressor/inotrope-resistant shock may be another
important indicator of the presence of hypoadrenal-
ism [12, 22]. The death rate for patients who experi-
ence unrecognized/inadequately treated adrenal
crisismay reach approximately 6%; in contrast, with
timely intervention symptoms usually resolve within
1 to 2 hours after parenteral corticosteroid adminis-
tration [38].
Amongst patients with AI, intercurrent infection/
sepsis is the most common factor precipitating the
development of adrenal crisis. Recent surgery and
advanced age are also recognized risk factors [39],
and certain pre-existing comorbidities have been
noted frequently amongst patients with adrenal
crisis, such as CVD, cancer, diabetes mellitus and
hypothyroidism [39, 40]. Up to 6% to 8% of patients
with AI have an adrenal crisis incident every year
[15, 38]. Owing to the nonspecific presentation of
AI, adrenal crisis may be the first presentation of
hypoadrenalism [22].
Longer-term consequences of AI include increased
mortality due to CVD, infections, cancer and
adrenal crisis [41, 42]; reduced bone mineral
density and increased prevalence of osteopenia
[43]; and poor health-related quality of life [44].
Assessment of HPA axis function
Given the apparent lack of symptoms in some
patients with AI and the nonspecific clinical fea-
tures in others, a low threshold for screening for AI
is required, especially in those with predisposing
factors (including exogenous corticosteroid expo-
sure) [12, 17, 19, 45]. This is supported by the
findings of a systematic review and meta-analysis
in which 10 of 521 (1.9%) patients reported symp-
toms consistent with AI, but after formal endocrine
testing, 98 (18.8%) patients met laboratory diag-
nostic thresholds for AI [6].
In general, most endocrinologists recommend that
screening for AI is not indicated until a patient has
been weaned to a physiologic dosage of corticos-
teroids, since, at higher dosages, the HPA axis
remains suppressed and testing may not accu-
rately reflect HPA axis reserve [26]. Several tests
are available to assess the HPA axis, each with its
merits and limitations.
9 Am serum cortisol
Although untimed random cortisol measurements
are generally discouraged when assessing the HPA
axis (reflecting the pulsatile and diurnal nature of
cortisol secretion), serum cortisol measurements at
9 AM may exclude or confirm the presence of
hypoadrenalism [11, 12]. For example, a 9 AM
serum cortisol level < 80 nmol/L indicates AI
[30], although in routine clinical practice val-
ues < 100 nmol/L are treated as indicative of
complete AI until further testing can confirm or
refute the diagnosis. In contrast, and in the
absence of confounding factors (as noted below),
a 9 AM serum cortisol > 400 nmol/L (with many
centres using even lower thresholds [e.g.
>350 nmol/L]) effectively excludes hypocorti-
solism. Values falling between these thresholds
are generally considered as indeterminate and may
be resolved by repeat testing or progressing to
dynamic testing. Of note, in a seriously ill patient
for whom hypoadrenalism is being considered, a
random sample should be collected (a low value in
this context is virtually diagnostic of AI) and
hydrocortisone commenced without delay, followed
by urgent referral to endocrinology.
That most clinical laboratories measure total
serum cortisol is important; elevated circulating
levels of cortisol-binding globulin (CBG), as
observed in pregnancy or in women receiving oral
oestrogen therapy, may result in apparently higher
cortisol concentrations being reported, which in
turn can mask true hypoadrenalism [46]. Similar
falsely reassuring results may also be seen after
synthetic ACTH stimulation [47]. Accordingly, a
discussion with a specialist endocrine team is
advisable if the assessment of adrenal reserve is
being considered in this context.
Corticotropin (synthetic ACTH1-24; tetracosactide;
cosyntropin) stimulation test
Various forms of the corticotropin (short Synac-
then, Cortrosyn) stimulation test exist. The short
ACTH stimulation test is the most widely used to
evaluate the integrity of the HPA axis [9–11, 48].
Corticosteroids, AI, and asthma / M. Gurnell et al.
6 ª The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine
Journal of Internal Medicine
This test assesses adrenal cortical reserve during
chronic ACTH deficiency [10] by directly stimulat-
ing the adrenal glands and infers the integrity of
the HPA axis based on peak response after ACTH
injection. A single dose (250 lg) of synthetic ACTH
is administered; blood samples are drawn imme-
diately before the test and at 30 (60) minutes after
ACTH injection to assess the rise in serum cortisol
[10, 11, 48]. Without normal ACTH production, the
adrenal glands atrophy and eventually demon-
strate an attenuated or absent response even to
direct stimulation by supraphysiologic ACTH. The
value of the test can be further enhanced by
performing it at 9 AM, thus allowing the interpreta-
tion of both the unstimulated and peak cortisol
responses.
Importantly, the short ACTH stimulation test
should not be used in the acute phase of suspected
secondary AI (e.g. within 6 weeks of pituitary
surgery) owing to the risk of a false-negative (i.e.
inappropriately reassuring) result [10], particularly
for a patient with secondary hypoadrenalism if the
adrenal glands have not yet atrophied. If testing is
carried out in this context, then the finding of a low
baseline concentration of cortisol, but with appar-
ent preserved peak cortisol response to synthetic
ACTH, should raise concerns of the possible early
phase of secondary AI. In recognition of this, the
low-dose (1 µg) short ACTH stimulation test has
been proposed as a more sensitive test for the
detection of secondary AI [10, 49], although the
lack of a suitable preparation to allow accurate
dosing has led some to call into question the
reliability of such a test. The long (depot) ACTH
stimulation test is now rarely used.
Other tests of HPA function
In certain cases, an insulin tolerance test or a
glucagon stimulation test may also be used to
assess HPA and adrenal function. However,
insulin-induced hypoglycaemia should only be
performed in a specialist endocrine unit and is
contraindicated in patients with known or sus-
pected seizures, arrhythmias or ischaemic heart
disease. Other specialist tests, including glucagon
stimulation, are also best performed in conjunc-
tion with endocrinology [50]. Collection of plasma
for ACTH measurement (to help distinguish pri-
mary [raised ACTH and low cortisol] from sec-
ondary [low/inappropriately normal ACTH and
low cortisol] AI) requires specific sample handling
and should be discussed with the endocrine
laboratory.
Treatment of secondary adrenal insufficiency
If glucocorticoid-induced AI is diagnosed, treat-
ment should be initiated as soon as possible. In an
acutely unwell patient, urgent rehydration and
hydrocortisone administration are required [51].
For chronic AI, glucocorticoid replacement is indi-
cated and should be administered in such a way as
to replicate circadian cortisol production as much
as possible [51]. Typically, hydrocortisone or pred-
nisolone is used [52, 53]. Since the recovery of HPA
axis function is possible, patients with AI conse-
quent on exogenous glucocorticoid use should not
automatically be assumed to require lifelong,
chronic corticosteroid replacement; weaning/ta-
pering may be feasible. In addition, in some
patients, full corticosteroid replacement may only
be necessary in emergencies or in situations of
stress or illness [51, 54]. Patient and caregiver
education is therefore vital in cases of AI; patients
must understand their condition and how their
needs for glucocorticoid replacement change
because of stress, illness or trauma [51]. A key
element of the safe management of AI is ensuring
that the patient, their relatives and healthcare
professionals are alert to the possibility of AI and
the need to rapidly intervene to prevent deteriora-
tion. Accordingly, the use of ‘steroid cards’, emer-
gency bracelets/necklaces and the provision of
‘steroid rescue packs’ containing additional oral
and parenteral glucocorticoid are strongly recom-
mended [7].
Asthma, oral corticosteroids and adrenal insufficiency
As stated, secondary AI can occur in many disease
states and as a result of taking several different
drugs. The use of corticosteroids, the most com-
mon drug-related cause of AI, is often traceable to
respiratory diseases, and asthma is a representa-
tive condition that can be used in determining OCS
use and the potential challenges and opportunities
related to corticosteroid-sparing therapies. Asthma
is a complex, multifactorial disease of airway
inflammation that typically includes symptoms of
wheezing, shortness of breath, chest tightness and
cough; the airway inflammation is usually chronic,
leading to expiratory airflow limitations [55].
Asthma is estimated to affect more than 350
million people around the world [56]. Severe
asthma only affects a relatively small percentage
of patients (approximately 5%–10%), but these
individuals are more likely to develop asthma-
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related symptoms and an increased risk of acute
exacerbations than those with less severe forms of
the disease [57–61]. The management of severe
asthma is difficult, and many patients require
treatment with high-dosage inhaled corticosteroids
plus a second controller, with or without systemic
corticosteroids (i.e. OCS), to maintain disease
control [62]. In addition to the use as maintenance
control therapy, OCS are also used for the treat-
ment of acute exacerbations [5, 16, 55]. As many as
30% to 45% of patients regularly use systemic
corticosteroids to control asthma symptoms [58–
61, 63, 64]. However, corticosteroids only suppress
type 2 (T2) inflammation, driven by IL-4, IL-5 and
IL-13, and primarily treat symptoms owing to this
type of inflammation. In the absence of T2 inflam-
mation, corticosteroids offer less improvement in
symptoms or disease control whilst putting
patients at risk of AEs [65].
Although OCS may offer asthma control for some
patients, frequent or continuous OCS use is asso-
ciated with systemic AEs and poor quality of life
[55, 58, 59, 66]. Additionally, long-term corticos-
teroid use in asthma is associated with increased
healthcare resource utilization for related AEs,
including physician visits, specialist visits, hospi-
talizations, emergency department visits and pre-
scriptions [67, 68]. Patients with asthma who are
exposed to corticosteroids have greater healthcare
costs than those without asthma, and those with
larger cumulative corticosteroid exposures have
greater costs than those exposed to lower cumula-
tive dosages. Overall, asthma confers substantial
personal and societal costs and causes an eco-
nomic burden of billions of dollars worldwide per
annum [67, 69–71].
Prevalence of adrenal insufficiency in asthma
The true prevalence of AI in asthma is difficult to
determine, in part, because of limited studies, as
well as a shortage of reliable interstudy compar-
isons [13, 34]. In one meta-analysis, 48.7% of
patients were diagnosed with AI after OCS use. The
population included patients who were using OCS
for multiple immune-related and inflammatory
conditions, including respiratory, dermatologic
and rheumatologic disorders; most patients had
been taking OCS for between 1 month and 1 year,
and most were taking a ‘medium dose’ of corticos-
teroids, designated as the range between the lower
and upper limits of the recommended dosages for
each corticosteroid [6]. When patients with asthma
were examined separately, the same analysis
observed that 11.1% of patients using corticos-
teroids had AI. Only 6.8% of patients taking solely
inhaled corticosteroids had AI, but 43.7% of those
individuals using OCS had AI. The risk of AI was
greater with longer durations of OCS use for
asthmatic patients (1.4% with short term
[<1 month] use, 11.9% during the medium term
[1 month–1 year] and 27.4% for the long term
[≥1 year]) [6].
Unfortunately, there is no established dosage or
duration of OCS that is determined to control
asthma symptoms without causing AEs [60].
Experts are calling for ‘OCS stewardship’ to reduce
the risks, including AI, related to OCS use [33]. To
mitigate the potential for AEs, OCS use should be
minimized by optimizing inhaled and biologic
therapies for asthma [55, 61]. The availability of
newer biologics has allowed for the advent of OCS-
sparing therapies in asthma, although the process
by which long-term corticosteroids should be
tapered and/or discontinued has not been estab-
lished. Consideration should be given to the risk of
symptom recurrence and withdrawal-induced AI
[33, 72].
In 2020, a consensus statement on the use of OCS
was issued by 131 practitioners of specialties who
frequently use OCS (mostly pulmonologists, respi-
ratory disease specialists and allergists). Of the
participating experts, more than 95% concurred
that, ultimately, the goal in asthma should be to
avoid the use of OCS. When OCS are required, the
dosage and duration should be minimized as much
as possible [33]. Experts also agreed that individ-
ualized tapering to a minimally effective dosage (or
complete discontinuation) should be attempted in
all patients receiving OCS for maintenance therapy
regardless of comorbid conditions [33]. For AI risk,
the experts agreed that AI is insufficiently assessed
and that patients on long-term OCS therapy
should be assessed for the risk and presence of
AI. This includes patients receiving OCS dosages in
excess of 2.0 g per year or more than 4 repeat
courses of short-term OCS in 1 year [33].
The Safest corticosteroids are the Fewest corticosteroids
For patients with severe, uncontrolled asthma
with T2 inflammation, reduction or elimination of
long-term OCS, without loss of control, can be
accomplished by using a biologic treatment
directed towards inflammatory mediators [2, 65].
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Omalizumab is a recombinant humanized mono-
clonal antibody that binds to IgE and decreases
the expression of IgE receptors on inflammatory
cells [73]; dupilumab is a fully human mono-
clonal antibody directed against the IL-4 receptor
that blocks both IL-4 signalling and IL-13 sig-
nalling and ultimately lessens inflammation [63];
mepolizumab and reslizumab are monoclonal
antibodies that act as IL-5 antagonists [57],
effectively neutralizing IL-5 [74] and selectively
inhibiting inflammation in the airways [1, 71, 75];
and benralizumab is an IL-5Ra-directed cytolytic
monoclonal antibody that directly binds to the IL-5
receptor and activates antibody-dependent cell-
mediated cytotoxicity, ultimately decreasing eosi-
nophilic inflammation [1, 59, 76–78].
Biologics have led to decreased OCS use, reduced
rates of exacerbations and improved symptom
control [3, 73, 76], and they are approved as add-
on therapy for patients with severe, persistent
asthma. Although the OCS-sparing results of both
clinical trials and real-world analyses of biologics
in asthma are promising, many studies used short
evaluation periods and small sample sizes. In
addition, cautious approaches were used to taper
OCS, given the placebo-controlled nature of some
of these studies, and AI was not consistently
monitored (Table 2) [57, 59, 63, 73, 78–88].
The PONENTE trial, the results of which are
expected in mid-2021, seeks to address the gaps
left by previous studies and answer key questions
to guide real-world clinical practice, including how
quickly long-term OCS can be tapered and how
best to monitor for and manage AI after introducing
benralizumab. PONENTE is the largest OCS-spar-
ing trial conducted to date, with a goal of including
approximately 600 patients, and is the only one to
directly address AI [78]. The PONENTE trial will
outline a personalized, rapid tapering of supra-
physiologic dosages of OCS based on OCS dosage
and asthma control, as well as provide guidance on
tapering OCS in the presence of suspected or
confirmed AI. The maintenance phase is also
substantially longer (24–32 weeks after the OCS
reduction phase) than most other studies (4 weeks)
[57, 59, 63]. This longer maintenance phase will
detail the long-term effectiveness and safety of
benralizumab after OCS reduction or elimination
[78].
There is currently a lack of clarity on the impact of
high-dosage topical glucocorticoids on the
development of AI in patients with severe asthma
irrespective of maintenance OCS use. By defini-
tion, all severe asthmatics are treated with high
dosages of inhaled corticosteroids and a significant
minority will be using topical nasal steroids for
allergic rhinitis or chronic rhinosinusitis with
nasal polyps. High-dosage inhaled corticosteroids
were an inclusion criterion for PONENTE, which
will make it possible to analyse whether or not
adrenal function can be recovered following OCS
withdrawal despite the continuation of high-dosage
inhaled corticosteroids.
Conclusions and future direction
Despite the advent of targeted biologics and OCS
drawbacks and disadvantages, corticosteroids con-
tinue to be used in asthma management. The goal
is to find ways to greatly reduce or eliminate their
long-term use and to better balance the safety and
effectiveness of asthma treatments [60].
There are gaps in knowledge and practice related to
OCS stewardship. Systemic corticosteroids are the
option of last resort in Global Initiative for Asthma
(GINA) Step 5 treatment, and GINA recommends
gradual decrease and/or discontinuation of OCS
after patients achieve a good response to biologic
therapies [33, 55]. Ideally, the role of OCS will
continue to narrow as the use of novel therapies
targeting specific pathways increases [33, 60].
In order to prevent both the systemic effects and
the development of AI associated with long-term
OCS use, steroid-sparing strategies are needed to
advance safety amongst patients with severe,
uncontrolled asthma [71, 77]. Treatments that
directly target airway inflammation offer improved
overall control of asthma and reduce OCS use [1,
77]. Biologic therapies greatly decrease the role of
OCS and, in many cases, eliminate their need
entirely.
Education is key to elevating awareness of optimal
asthma control for patients, as well as steroid-
sparing strategies amongst clinicians [30]. Ongo-
ing clinical trials are already changing clinical
practice by guiding the tapering of OCS and the
screening and management of AI after introducing
biologics [78]. Importantly, substantial and long-
lasting modifications in prescribing patterns of
OCS may well require changes to healthcare sys-
tems and collaborations amongst different spe-
cialties [30].
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